Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy (IPG274)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 September 2008
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cellvizio confocal endomicroscopy system for characterising pancreatic cysts (MIB69)Product type:AdviceProgramme:Medtech innovation briefingPublished: 28 June 2016
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction (IPG794)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 November 2024
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinomaStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Irreversible electroporation for treating pancreatic cancer (IPG579)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 3 May 2017
Laparoscopic distal pancreatectomy (IPG204)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 January 2007
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal) (TA750)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 December 2021
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Pancreas SABRStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Pancreatic cancer in adults: diagnosis and management (NG85)Product type:GuidanceProgramme:NICE guidelinePublished: 7 February 2018
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 April 2017
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2024
Percutaneous intraductal radiofrequency ablation for malignant biliary obstructionStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer TSID 12040Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC